Back to Authors

Shankar, D.

https://orcid.org/0000-0002-2433-4895

Mayo Clinic

Boston Medical Center

Citations 2

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
Bhat, Shubha , Altajar, Sarah, Shankar, D. , Zahorian, Toni, Robert, Regine, Qazi, Taha , Shah, Bhavesh , Shah, Bhavesh, Farraye, Francis A.

Journal of Managed Care & Specialty Pharmacy | March 30, 2020 | Volume: 26 | Issue: 4 | Pages: 410-416

10.18553/jmcp.2020.26.4.410 Get It

The Use of An EHR Patient Portal (Mychart-Epic) in Patients With Inflammatory Bowel Disease
Reich, Jason , Canakis, Andrew , Harrington, Jill E., Apte, Manisha, Jones, Eric A., Noronha, Ansu, Canakis, Andrew , Shankar, D. , Weinberg, Janice , Wasan, Sharmeel K. , Farraye, Francis A.

Crohn's & Colitis 360 | October 12, 2019 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/crocol/otz039 Get It

Abstract Introduction Inflammatory bowel disease (IBD) has a significant effect on patients’ overall quality of life (QoL). We hypothesized that an Electronic Health Record (EHR) patient portal (EPIC’s Mychart) can be utilized to improve QoL in IBD patients and increase vaccine uptake. Methods Patients were randomized to receive specific disease (INT) information and to a control arm (CTRL) that received periodic non-IBD related messages. Disease severity was assessed using the Harvey-Bradshaw index, and Simple Clinical Colitis Activity index. QoL was measured using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Secondary outcome measures included overall satisfaction with the portal and influenza and pneumococcal vaccine uptake. Results One hundred twenty-seven patients were randomized: At baseline the CTRL group had a statistically significant higher QoL (Median SIBDQ 53.7) compared with the INT group (median SIBDQ 49.3), P = 0.04. At 6 months, the INT group had a trend towards a significantly greater increase in QoL (median SIBDQ 58) when compared with the CTRL group (median SIBDQ 57.5), P = 0.06. At 6 months more frequent portal use showed a significantly lower median SIBDQ (median 53) compared with patients with less frequent portal use (median 59), P = 0.038. At 6 months 88% of patients felt that the MyChart portal was useful with respect to IBD management. Patients had high rates of portal utilization with one-third of patients logging on weekly, and one-third logging on monthly. With respect to vaccine uptake, both influenza and pneumococcal pneumonia had higher rates of vaccine uptake. Conclusions Patients showed a trend towards improved QoL after receiving disease-specific information through our EHR portal. A significant increase in vaccine uptake was also seen. Frequent automated messages sent via an EHR portal can improve patient’s overall QoL. Larger studies will be needed to determine if automated portal reminders have a significant association with improved QoL, and furthermore to determine if there is any impact on disease activity.